Announcement of Jorg Becoming President Elect

Richmond Pharmacology is delighted to announce that its CEO Jorg Taubel has been appointed President Elect of The Association for Applied Human Pharmacology(AGAH), Germany. The AGAH is an organisation for everyone dealing with clinical pharmacological test programmes, studies in the target population in early-stage medicinal product development and translational topics. Its members play an active part in the pro­fes­sional sci­en­tific de­vel­op­ment of phar­ma­ceu­ti­cal re­search and come from phar­ma­ceu­ti­cal com­pa­nies, uni­ver­si­ties or other re­search fa­cil­i­ties, con­tract re­search or­gan­i­sa­tions and com­pe­tent au­thor­i­ties. Dr Taubel’s term will be six years: president elect for two years, president2026-28 and past president 2020-30.

Dr Jorg Taubel, MD FFPM FESC, is both CEO and co-founder of Richmond Pharmacology, and a prominent figure in clinical pharmacology, with a specialisation that extends through cardiology, neurology, and more. His expertise has been pivotal in over 500 clinical trials, especially as an MHRA-recognized investigator for First in Human trials. Notably, Dr Taubel led the ground breaking NTLA-2001clinical trial, pioneering the use of CRISPR-Cas9 gene editing for TTR amyloidosis, marking a significant advancement in treatment options. Additionally, his commitment to medical progress is evident in founding the Richmond Research Institute, focusing on enhancing healthcare through research. His work symbolises a blend of innovation, dedication, and a drive for excellence in medical science.

DrTaubel said: “I am honoured to have been appointed President Elect of AGAH. The organisation has always been an excellent training provider for clinical pharmacology and early phase medicines research. I look forward to maintaining this rich heritage and to making it even stronger in the future. I am committed to enhancing its ability to inspire more young people to lead more trials in the future. With that will come an increase in knowledge and expertise at the forefront of medicine and pharmacology reaping the benefits of potential medicines directed at genetic targets. The AGAH has a key role to play ingrowing the pool of doctors and other professionals active in early phase clinical research and to work constructively with stakeholders to provide important input into guidelines governing the testing of potential new medicines.”